Free Trial
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel Free VINC Stock Alerts

Vincerx Pharma (VINC) Competitors

Vincerx Pharma logo
$0.03 0.00 (0.00%)
As of 10/13/2026
Compare

VINC vs. SRNE, AMPE, PRPH, VRPX, and PTPI

Should you buy Vincerx Pharma stock or one of its competitors? Vincerx Pharma's main competitors and comparable companies include Sorrento Therapeutics (SRNE), Ampio Pharmaceuticals (AMPE), ProPhase Labs (PRPH), Virpax Pharmaceuticals (VRPX), and Petros Pharmaceuticals (PTPI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Vincerx Pharma compare to Sorrento Therapeutics?

Vincerx Pharma (NASDAQ:VINC) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Vincerx Pharma has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market. Comparatively, Sorrento Therapeutics has a beta of -0.02, indicating that its stock price is 102% less volatile than the broader market.

Vincerx Pharma has higher earnings, but lower revenue than Sorrento Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vincerx PharmaN/AN/A-$40.16M-$5.31N/A
Sorrento Therapeutics$60.32M0.00-$572.84MN/AN/A

Sorrento Therapeutics' return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Vincerx PharmaN/A -248.33% -132.73%
Sorrento Therapeutics N/A N/A N/A

44.0% of Vincerx Pharma shares are held by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are held by institutional investors. 15.6% of Vincerx Pharma shares are held by company insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Vincerx Pharma's average media sentiment score of 0.00 equaled Sorrento Therapeutics'average media sentiment score.

Company Overall Sentiment
Vincerx Pharma Neutral
Sorrento Therapeutics Neutral

Summary

Vincerx Pharma beats Sorrento Therapeutics on 5 of the 8 factors compared between the two stocks.

How does Vincerx Pharma compare to Ampio Pharmaceuticals?

Vincerx Pharma (NASDAQ:VINC) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vincerx PharmaN/AN/A-$40.16M-$5.31N/A
Ampio PharmaceuticalsN/AN/A-$8.63M-$11.01N/A

44.0% of Vincerx Pharma shares are held by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are held by institutional investors. 15.6% of Vincerx Pharma shares are held by company insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Ampio Pharmaceuticals' return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Vincerx PharmaN/A -248.33% -132.73%
Ampio Pharmaceuticals N/A N/A N/A

In the previous week, Vincerx Pharma's average media sentiment score of 0.00 equaled Ampio Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Vincerx Pharma Neutral
Ampio Pharmaceuticals Neutral

Vincerx Pharma has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market. Comparatively, Ampio Pharmaceuticals has a beta of 5.96, indicating that its stock price is 496% more volatile than the broader market.

Summary

Vincerx Pharma and Ampio Pharmaceuticals tied by winning 4 of the 8 factors compared between the two stocks.

How does Vincerx Pharma compare to ProPhase Labs?

Vincerx Pharma (NASDAQ:VINC) and ProPhase Labs (NASDAQ:PRPH) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

In the previous week, ProPhase Labs had 1 more articles in the media than Vincerx Pharma. MarketBeat recorded 1 mentions for ProPhase Labs and 0 mentions for Vincerx Pharma. Vincerx Pharma's average media sentiment score of 0.00 equaled ProPhase Labs'average media sentiment score.

Company Overall Sentiment
Vincerx Pharma Neutral
ProPhase Labs Neutral

Vincerx Pharma has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market. Comparatively, ProPhase Labs has a beta of 0.13, meaning that its stock price is 87% less volatile than the broader market.

44.0% of Vincerx Pharma shares are held by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are held by institutional investors. 15.6% of Vincerx Pharma shares are held by insiders. Comparatively, 9.6% of ProPhase Labs shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Vincerx Pharma has higher earnings, but lower revenue than ProPhase Labs. Vincerx Pharma is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vincerx PharmaN/AN/A-$40.16M-$5.31N/A
ProPhase Labs$5.06M0.04-$53.36M-$2.25N/A

Vincerx Pharma has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Vincerx Pharma's return on equity of -248.33% beat ProPhase Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
Vincerx PharmaN/A -248.33% -132.73%
ProPhase Labs -825.01%-482.05%-88.90%

Summary

Vincerx Pharma beats ProPhase Labs on 7 of the 11 factors compared between the two stocks.

How does Vincerx Pharma compare to Virpax Pharmaceuticals?

Virpax Pharmaceuticals (NASDAQ:VRPX) and Vincerx Pharma (NASDAQ:VINC) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Virpax Pharmaceuticals has a beta of -214.69, suggesting that its stock price is 21,569% less volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market.

Vincerx Pharma is trading at a lower price-to-earnings ratio than Virpax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A
Vincerx PharmaN/AN/A-$40.16M-$5.31N/A

32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are owned by institutional investors. 3.7% of Virpax Pharmaceuticals shares are owned by company insiders. Comparatively, 15.6% of Vincerx Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Vincerx Pharma'saverage media sentiment score.

Company Overall Sentiment
Virpax Pharmaceuticals Neutral
Vincerx Pharma Neutral

Vincerx Pharma's return on equity of -248.33% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Virpax PharmaceuticalsN/A -1,554.34% -338.29%
Vincerx Pharma N/A -248.33%-132.73%

Summary

Vincerx Pharma beats Virpax Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

How does Vincerx Pharma compare to Petros Pharmaceuticals?

Petros Pharmaceuticals (NASDAQ:PTPI) and Vincerx Pharma (NASDAQ:VINC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are held by institutional investors. 12.3% of Petros Pharmaceuticals shares are held by company insiders. Comparatively, 15.6% of Vincerx Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Petros Pharmaceuticals has higher revenue and earnings than Vincerx Pharma. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Petros Pharmaceuticals$5.11M0.02-$8.16M-$0.36N/A
Vincerx PharmaN/AN/A-$40.16M-$5.31N/A

Petros Pharmaceuticals' return on equity of -78.22% beat Vincerx Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Petros PharmaceuticalsN/A -78.22% -23.50%
Vincerx Pharma N/A -248.33%-132.73%

Petros Pharmaceuticals has a beta of 1.87, indicating that its share price is 87% more volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market.

In the previous week, Petros Pharmaceuticals' average media sentiment score of 0.00 equaled Vincerx Pharma'saverage media sentiment score.

Company Overall Sentiment
Petros Pharmaceuticals Neutral
Vincerx Pharma Neutral

Summary

Petros Pharmaceuticals beats Vincerx Pharma on 7 of the 9 factors compared between the two stocks.

Get Vincerx Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for VINC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VINC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VINC vs. The Competition

Export
MetricVincerx PharmaPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$135K$12.13B$7.18B$13.18B
Dividend YieldN/A2.63%2.52%19.60%
P/E Ratio0.00641.56203.7919.22
Price / SalesN/A749.43557.6574.70
Price / CashN/A84.0876.6852.75
Price / Book0.009.1510.515.92
Net Income-$40.16M$2.82B$3.50B$380.90M
7 Day PerformanceN/A-3.80%-3.51%-3.85%
1 Month PerformanceN/A-7.64%-7.77%-6.37%
1 Year PerformanceN/A-6.14%0.80%-6.01%

Vincerx Pharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VINC
Vincerx Pharma
N/A$0.03
flat		N/AN/A$135KN/AN/A60
SRNE
Sorrento Therapeutics
N/A$0.00
flat		N/A-96.0%$245K$60.32MN/A949
AMPE
Ampio Pharmaceuticals
N/A$0.18
flat		N/AN/A$208KN/AN/A6
PRPH
ProPhase Labs
N/A$0.01
-9.6%		N/A-99.8%$196K$5.06MN/A130
VRPX
Virpax Pharmaceuticals
N/AN/AN/A-96.2%$193KN/AN/A2

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:VINC) was last updated on 10/15/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel